ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Construction and validation of a prognostic model for 1 year all-cause mortality risk in patients with colorectal cancer liver metastases after HIFU treatment.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeColorectal cancer liver metastases (CRLM) worsen the prognosis of patients. High-intensity focused ultrasound (HIFU) is a non-invasive treatment for CRLM, but reliable prognostic tools for HIFU patients are lacking. This study aimed to develop and validate a nomogram to predict the risk of 1-year all-cause mortality (ACM) in patients with CRLM receiving HIFU.
methodsThis retrospective cohort study enrolled patients with CRLM who received HIFU between January 2014 and December 2023 at two medical centers. Data from Chongqing Medical University's Second Affiliated Hospital were used as the training set, while data from Suining Central Hospital were used as the external validation set. Feature selection was performed using the least absolute shrinkage and selection operator (LASSO) regression to identify relevant predictors and establish a nomogram. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
resultsAmong 162 patients (121 in the training set, 41 in the validation set), the 1 year ACM rates were 31.4% and 24.4%, respectively. LASSO regression identified six predictors: sex, number of liver metastases, extrahepatic metastases status, number of extrahepatic organs involved, alkaline phosphatase level (ALP), and albumin level (ALB). The nomogram demonstrated robust performance, with an area under the curve (AUC) of 0.886 (95% CI: 0.816-0.956) in the training set and 0.706 (95% CI: 0.495-0.918) in the validation set. Calibration curves showed good agreement, and DCA confirmed its clinical utility.
conclusionA nomogram was developed and externally validated, which provides clinicians with an accurate and reliable tool for individualized prognostic assessment and treatment optimization in patients with CRLM undergoing HIFU.
Indexed as
Identifiers
41874948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.